It has been shown in many clinical studies that the level of vascular endothelial growth factor-C (VEGF-C) positively correlates with lymph node metastasis. Nevertheless, beyond the canonical role of VEGF-C in stimulating lymphangiogenesis and thus promoting lymph node/distant metastasis, emerging evidence indicates that expression of VEGF-C contributes to various aspects of carcinogenicity via autocrine regulation. The newly identified functions of VEGF-C include but are not limited to proliferation, migration, invasion, and chemo-resistance. Besides tumor cell autocrine regulation, VEGF-C can also modulate the immune system such that tumor cells more easily escape immune surveillance. Therefore, understanding the functional roles and regulatory mechanisms related to the VEGF-C axis may lead to alternative strategies for cancer treatment. This mini-review will focus on summarizing recent discoveries regarding the unconventional functions of VEGF-C in cancer progression.
LohelaMBryMTammelaTAlitaloK. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol2009; 21: 154–65.
2.
OtrockZKMakaremJAShamseddineAI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis2007; 38: 258–68.
3.
JoukovVPajusolaKKaipainenAChilovDLahtinenIKukkESakselaOKalkkinenNAlitaloK. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J1996; 15: 290–98.
4.
KarkkainenMJHaikoPSainioKPartanenJTaipaleJPetrovaTVJeltschMJacksonDGTalikkaMRauvalaHBetsholtzCAlitaloK. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nature Immunol2004; 5: 74–80.
5.
MakinenTVeikkolaTMustjokiSKarpanenTCatimelBNiceECWiseLMercerAKowalskiHKerjaschkiDStackerSAAchenMGAlitaloK. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J2001; 20: 4762–73.
6.
SalamehAGalvagniFBardelliMBussolinoFOlivieroS. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood2005; 106: 3423–31.
7.
Prud’hommeGJGlinkaY. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget2012; 3: 921–39.
8.
FavierBAlamABarronPBonninJLaboudiePFonsPMandronMHeraultJPNeufeldGSaviPHerbertJMBonoF. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood2006; 108: 1243–50.
9.
MasP. Seminars in cell and developmental biology. Plant circadian rhythms. Preface. Semin Cell Dev Biol2013; 24: 381–2.
10.
XuYYuanLMakJPardanaudLCauntMKasmanILarriveeBDel ToroRSuchtingSMedvinskyASilvaJYangJThomasJLKochAWAlitaloKEichmannABagriA. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol2010; 188: 115–30.
11.
DecioATarabolettiGPattonVAlzaniRPeregoPFruscioRJurgensmeierJMGiavazziRBelottiD. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol2014; 184: 1050–61.
12.
KinoshitaJKitamuraKKabashimaASaekiHTanakaSSugimachiK. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat2001; 66: 159–64.
13.
KimuraHKatoHTanakaNInoseTFariedASohdaMNakajimaMFukaiYMiyazakiTMasudaNMandaRFukuchiMOjimaHTsukadaKKuwanoH. Preoperative serum vascular endothelial growth factor-C (VEGF-C) levels predict recurrence in patients with esophageal cancer. Anticancer Res2008; 28: 165–9.
14.
MohammedRAGreenAEl-ShikhSPaishECEllisIOMartinSG. Prognostic significance of vascular endothelial cell growth factors-A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer2007; 96: 1092–100.
15.
KigureWFujiiTSutohTMoritaHKatohTYajimaRNYamaguchiSTsutsumiSAsaoTKuwanoH. The association of VEGF-C expression with tumor lymphatic vessel density and lymph node metastasis in patients with gastric cancer and gastrointestinal stromal tumor. Hepato-gastroenterology2013; 60: 277–80.
16.
ZhaoYCNiXJWangMHZhaXMZhaoYWangS. Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients. Med Oncol2012; 29: 2594–600.
17.
TanakaTIshiguroHKuwabaraYKimuraMMitsuiAKatadaTShiozakiMNaganawaYFujiiYTakeyamaH. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res2010; 29: 83–83.
18.
JennbackenKVallboCWangWDamberJE. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate2005; 65: 110–6.
19.
SoumaoroLTUetakeHTakagiYIidaSHiguchiTYasunoMEnomotoMSugiharaK. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum2006; 49: 392–8.
20.
SkobeMHawighorstTJacksonDGPrevoRJanesLVelascoPRiccardiLAlitaloKClaffeyKDetmarM. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med2001; 7: 192–8.
21.
MattilaMMRuoholaJKKarpanenTJacksonDGAlitaloKHarkonenPL. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer2002; 98: 946–51.
FielderWGraevenUErgunSVeragoSKilicNStockschladerMHossfeldDK. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia1997; 11: 1234–7.
24.
DiasSChoyMAlitaloKRafiiS. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood2002; 99: 2179–84.
25.
LimJJYangKTaylor-HardingBWiedemeyerWRBuckanovichRJ. VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia2014; 16: 343–53.
26.
SuJLYangPCShihJYYangCYWeiLHHsiehCYChouCHJengYMWangMYChangKJHungMCKuoML. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell2006; 9: 209–23.
27.
TimoshenkoAVRastogiSLalaPK. Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br J Cancer2007; 97: 1090–8.
28.
ChenYJiangLSheFTangNWangXLiXHanSZhuJ. Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism. Mol Cell Biochem2010; 345: 77–89.
29.
LiuPZhouJZhuHXieLWangFLiuBShenWYeWXiangBZhuXShiRZhangS. VEGF-C promotes the development of esophageal cancer via regulating CNTN-1 expression. Cytokine2011; 55: 8–17.
30.
MudersMHZhangHWangETindallDJDattaK. Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res2009; 69: 6042–8.
31.
StantonMJDuttaSZhangHPolavaramNSLeontovichAAHonscheidPSinicropeFATindallDJMudersMHDattaK. Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res2013; 73: 160–71.
32.
WangCAHarrellJIwanagaRJedlickaPFordHL. Vascular endothelial growth factor-C promotes breast cancer progression via a novel anti-oxidant mechanism that involves regulation of Superoxide dismutase 3. Breast Cancer Res2014; 16: 462–462.
33.
CaoYHoeppnerLHBachSEGGuoYWangEWuJCowleyMJChangDKWaddellNGrimmondSMBiankinAVDalyRJZhangXMukhopadhyayD. Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial alpha5 integrin. Cancer Res2013; 73: 4579–90.
34.
NasarrePGemmillRMPotironVARocheJLuXBaronAEKorchCGarrett-MayerELaganaAHowePHDrabkinHA. Neuropilin-2 Is upregulated in lung cancer cells during TGF-beta1-induced epithelial-mesenchymal transition. Cancer Res2013; 73: 7111–21.
35.
GoelHLPursellBChangCShawLMMaoJSiminKKumarPVander KooiCWShultzLDGreinerDLNorumJHToftgardRKuperwasserCMercurioAM. GLI1 regulates a novel neuropilin-2/alpha6beta1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med2013; 5: 488–508.
36.
KhromovaNKopninPRybkoVKopninBP. Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene2012; 31: 1389–97.
37.
PontiDCostaAZaffaroniNPratesiGPetrangoliniGCoradiniDPilottiSPierottiMADaidoneMG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res2005; 65: 5506–11.
38.
DingMFuXTanHWangRChenZDingS. The effect of vascular endothelial growth factor C expression in tumor-associated macrophages on lymphangiogenesis and lymphatic metastasis in breast cancer. Mol Med Rep2012; 6: 1023–9.
TakahashiAKonoKItakuraJAmemiyaHFeng TangRIizukaHFujiiHMatsumotoY. Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology2002; 62: 121–7.
41.
LeeJYParkSKimDCYoonJHShinSHMinWSKimHJ. A VEGFR-3 antagonist increases IFN-gamma expression on low functioning NK cells in acute myeloid leukemia. J Clin Immunol2013; 33: 826–37.
42.
LeeJYParkSMinWSKimHJ. Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemia. Cancer Lett2014; 354: 281–9.
43.
ChenZVarneyMLBackoraMWCowanKSolheimJCTalmadgeJESinghRK. Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival. Cancer Res2005; 65: 9004–11.
44.
LundAWDuraesFVHirosueSRaghavanVRNembriniCThomasSNIssaAHuguesSSwartzMA. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep2012; 1: 191–9.
45.
KukkELymboussakiATairaSKaipainenAJeltschMJoukovVAlitaloK. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development1996; 122: 3829–37.
46.
ZhangHMudersMHLiJRinaldoFTindallDJDattaK. Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res2008; 68: 8770–8.
47.
WangCAJedlickaPPatrickANMicalizziDSLemmerKCDeitschECasas-SelvesMHarrellJCFordHL. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. J Clin Invest2012; 122: 1895–906.
48.
LinFJChenXQinJHongYKTsaiMJTsaiSY. Direct transcriptional regulation of neuropilin-2 by COUP-TFII modulates multiple steps in murine lymphatic vessel development. J Clin Invest2010; 120: 1694–707.
49.
ChoHJKimIKParkSMBaekKENamIKParkSHRyuKJChoiJRyuJHongSCJeongSHLeeYJKoGHKimJWon LeeCSoo KangSYooJ. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer2014; 135: 1553–63.
50.
DongZWeiFZhouCSumidaTHamakawaHHuYLiuS. Silencing Id-1 inhibits lymphangiogenesis through down-regulation of VEGF-C in oral squamous cell carcinoma. Oral Oncol2011; 47: 27–32.
51.
ChenCGTangPYuZT. [Effect of HMGB1 on the VEGF-C expression and proliferation of esophageal squamous cancer cells]. Zhonghua Zhong Liu Za Zhi [Chinese J Oncol]2012; 34: 566–70.
52.
OlofssonBPajusolaKvon EulerGChilovDAlitaloKErikssonU. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem1996; 271: 19310–7.
53.
ShinrikiSJonoHUedaMOtaKOtaTSueyoshiTOikeYIbusukiMHirakiANakayamaHShinoharaMAndoY. Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma. J Pathol2011; 225: 142–50.
54.
EnholmBPaavonenKRistimakiAKumarVGunjiYKlefstromJKivinenLLaihoMOlofssonBJoukovVErikssonUAlitaloK. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene1997; 14: 2475–83.
55.
RistimakiANarkoKEnholmBJoukovVAlitaloK. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem1998; 273: 8413–8.
56.
von RahdenBHSteinHJPuhringerFKochILangerRPiontekGSiewertJRHoflerHSarbiaM. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res2005; 65: 5038–44.
57.
TimoshenkoAVChakrabortyCWagnerGFLalaPK. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer2006; 94: 1154–63.
58.
LiuHXiaoJYangYLiuYMaRLiYDengFZhangY. COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer. Microvasc Res2011; 82: 131–40.
59.
Cohen-KaplanVNaroditskyIZetserAIlanNVlodavskyIDoweckI. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer2008; 123: 2566–73.
60.
XiangLXieGOuJWeiXPanFLiangH. The extra domain A of fibronectin increases VEGF-C expression in colorectal carcinoma involving the PI3K/AKT signaling pathway. PLoS One2012; 7: e35378–e35378.
61.
LuangdilokSBoxCHarringtonKRhys-EvansPEcclesS. MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck. Eur J Cancer2011; 47: 520–9.
62.
TsaiPWShiahSGLinMTWuCWKuoML. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. J Biol Chem2003; 278: 5750–9.
63.
YeJWuXWuDWuPNiCZhangZChenZQiuFXuJHuangJ. miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS One2013; 8: e60687–e60687.
64.
HirataHHinodaYUenoKShahryariVTabatabaiZLDahiyaR. MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis2012; 33: 41–8.
65.
HuJChengYLiYJinZPanYLiuGFuSZhangYFengKFengY. microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C. Eur J Cancer2014; 50: 2336–50.
66.
MorfoisseFKuchnioAFrainayCGomez-BrouchetADelisleMBMarziSHelferACHantelysFPujolFGuillermet-GuibertJBousquetCDewerchinMPyronnetSPratsACCarmelietPGarmy-SusiniB. Hypoxia induces VEGF-C expression in metastatic tumor cells via a HIF-1alpha-independent translation-mediated mechanism. Cell Rep2014; 6: 155–67.
67.
MatsumuraSOueNMitaniYKitadaiYYasuiW. DNA demethylation of vascular endothelial growth factor-C is associated with gene expression and its possible involvement of lymphangiogenesis in gastric cancer. Int J Cancer2007; 120: 1689–95.
68.
JoukovVSorsaTKumarVJeltschMClaesson-WelshLCaoYSakselaOKalkkinenNAlitaloK. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J1997; 16: 3898–911.
69.
SiegfriedGBasakACromlishJABenjannetSMarcinkiewiczJChretienMSeidahNGKhatibAM. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest2003; 111: 1723–32.
ChenJCChangYWHongCCYuYHSuJL. The role of the VEGF-C/VEGFRs Axis in tumor progression and therapy. Int J Mol Sci2012; 14: 88–107.
72.
HeYKozakiKKarpanenTKoshikawaKYla-HerttualaSTakahashiTAlitaloK. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst2002; 94: 819–25.
73.
RobertsNKloosBCassellaMPodgrabinskaSPersaudKWuYPytowskiBSkobeM. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res2006; 66: 2650–7.
74.
ParkerMWVander KooiCW. Microplate-based screening for small molecule inhibitors of neuropilin-2/vascular endothelial growth factor-C interactions. Anal Biochem2014; 453: 4–6.
75.
ZhaoYCNiXJLiYDaiMYuanZXZhuYYLuoCY. Peritumoral lymphangiogenesis induced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients. World J Surg Oncol2012; 10: 165–165.
76.
KoyamaYKanekoKAkazawaKKanbayashiCKandaTHatakeyamaK. Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer: association with lymph node metastasis. Clin Breast Cancer2003; 4: 354–60.
LiDXieKDingGLiJChenKLiHQianJJiangCFangJ. Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. Cancer Lett2014; 346: 45–52.
79.
SunPGaoJLiuYLWeiLWWuLPLiuZY. RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances epirubicin sensitivity of breast cancer cells. Mol Cell Biochem2008; 308: 161–8.
80.
HeMChengYLiWLiuQLiuJHuangJFuX. Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer2010; 10: 170–170.
81.
ChenHSuoKChengYZhengBXuL. Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase. Gynecol Endocrinol2013; 29: 20–4.
82.
Su CM, Su YH, Chiu CF, Chang YW, Hong CC, Yu YH, Ho YS, Wu CH, Yen CS, Su JL. Vascular endothelial growth factor-C upregulates cortactin and promotes metastasis of esophageal squamous cell carcinoma. Ann Surg Oncol 2014;21:767-775.
83.
HuaKTLeeWJYangSFChenCKHsiaoMKuCCWeiLHKuoMLChienMH. Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2. Biochim Biophys Acta2014; 1843: 387–97.
